Apatinib as Salvage Therapy for Heavily Pretreated SCLC.
10.3779/j.issn.1009-3419.2018.07.11
- Author:
Fangfang LI
1
;
Haitao TAO
2
Author Information
1. Department of State Guest, Institute of Health Management, the Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Oncology, the Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Case Reports
- Keywords:
Angiogenesis;
Apatinib;
Gilbert syndrome;
Small cell lung cancer
- MeSH:
Disease-Free Survival;
Humans;
Lung Neoplasms;
diagnosis;
drug therapy;
Middle Aged;
Pyridines;
therapeutic use;
Salvage Therapy;
Small Cell Lung Carcinoma;
diagnostic imaging;
drug therapy;
Tomography, X-Ray Computed;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2018;21(7):565-570
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) was highly malignant and lack effective treatment after the failure of radiotherapy and chemotherapy. Antiangiogenic therapy had shown a certain effect in advanced SCLC. Apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), showed the effect of anti-angiogenesis. However, the efficacy in SCLC was rarely reported. We reported 1 case of advanced SCLC with Gilbert syndrome, the patient received Apatinib after the failure of 4 lines of chemotherapy, and achieved a partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard after one month. The progression-free survival (PFS) was 5 months. Apatinib was well tolerated except recurrent grade 3 hyperbilirubinemia because of the metabolic disorder of Bilirubin. Salvage treatment with Apatinib for advanced SCLC deserved further exploration.
.
